In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

UCB and Celltech to develop and market CDP870 for arthritis

Executive Summary

Celltech Group PLC has licensed UCB SA development and marketing rights to CDP870, its anti-TNF-alpha PEGylated antibody fragment. The license is exclusive for rheumatoid arthritis and other indications, excluding Crohn's disease. Celltech has retained exclusive development and commercialization rights for Crohn's in North America, major European markets, Australia, and New Zealand, with UCB getting development and commercialization rights in other territories.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies